Hikal receives 'Hold' rating from MarketsMOJO, shows technical improvement and interest from institutional investors

Hikal, a smallcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO. The stock has shown a technical improvement from Mildly Bearish to Mildly Bullish on 06-Jun-24, with its KST and OBV technical factors also being Bullish. The company has a Fair valuation with a ROCE of 7.5 and an Enterprise value to Capital Employed ratio of 2.2. It is currently trading at a discount compared to its average historical valuations. However, in the past year, the stock has generated a return of -11.99%, while its profits have fallen by -11.2%. Institutional investors have shown an increasing interest in Hikal, with their stake in the company rising by 0.79% in the previous quarter. This indicates that these investors, who have better resources and capabilities to analyze company fundamentals, see potential in Hikal. However, the company has shown poor long-term growth with an annual rate of -7.64% in operating profit over the last 5 years. In the latest financial results for Mar 24, the company's PAT(9M) has grown at -28.16%, with its ROCE(HY) at its lowest at 7.57% and CASH AND CASH EQUIVALENTS(HY) at its lowest at Rs 20.77 cr. Hikal has also consistently underperformed against the benchmark over the last 3 years, with -11.99% returns in the last 1 year and underperformance against BSE 500 in each of the last 3 annual periods. While the stock may have potential, it is important to consider its past performance and current financial situation before making any investment decisions.